This post was originally published on this site Men who father children through assisted reproduction techniques, either in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), may be at a higher risk of developing prostate cancer, a study shows. Early screening for prostate cancer may also be beneficial for infertile men, according to the study,…
Category: <span>Cancer</span>
First Patient Enrolled in Trial Testing Defitelio to Prevent Neurotoxicity in DLBCL Patients Receiving CAR T-cell Therapy
This post was originally published on this site Jazz Pharmaceuticals has enrolled the first participant in a Phase 2 trial assessing the efficacy of Defitelio (defibrotide) to prevent nerve cell toxicity in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are receiving chimeric antigen receptor (CAR) T-cell therapy. The multicenter open-label trial…
$1.8M NIH Award to Support Work into Robotic System Able to Better Detect Prostate Cancer
This post was originally published on this site Haichong Zhang, an assistant professor at Worcester Polytechnic Institute, has been given a Director’s Early Independence Award from the National Institutes of Health (NIH) to support his work in designing a robotic system to better detect and monitor prostate cancer. Currently, prostate cancer is diagnosed via a blood…
Syros’ SY-5609 Shows Promising Activity in OC Models, Supports Planned Phase 1 Trial, Results Show
This post was originally published on this site Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The findings support the initiation of a Phase 1 trial testing the compound early next year, investigators said. Researchers…
Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows
This post was originally published on this site U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio (selinexor) as a fifth-line combination therapy, according to a survey conducted by market research firm Spherix Global Insights. The…
Opdivo-Yervoy Plus Shorter Chemotherapy Course Extends Survival of Patients with Advanced Lung Cancer, Early Trial Data Show
This post was originally published on this site First-line treatment with a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) added to a shorter course of chemotherapy significantly extends the survival of people with advanced non-small cell lung cancer (NSCLC), compared to standard chemotherapy alone, early Phase 3 trial results show. The CheckMate-9LA trial (NCT03215706)…
First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer
This post was originally published on this site A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company announced. The trial — called HER2CLIMB-02 (NCT03975647) — is enrolling up to 460 adult patients with metastatic…
Veru Completes Enrollment for Zuclomiphene Citrate Trial for ADT-Induced Hot Flashes in PC
This post was originally published on this site Veru Healthcare has completed patient enrollment for its Phase 2 clinical trial evaluating the use of zuclomiphene citrate (VERU-944) for the treatment of hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are experienced by about 80% of men on androgen deprivation therapy (ADT). ADT…
Transbronchial Lung Cryobiopsy Helps Provide Definitive Diagnose of Sarcoidosis, Study Suggests
This post was originally published on this site Transbronchial lung cryobiopsy — a relatively new method of collecting lung tissue for analysis — safely and successfully helps to provide a definitive sarcoidosis diagnosis when the usual and less-invasive diagnostic tools are insufficient, a Portuguese study suggests. The study, “Diagnostic yield and safety of transbronchial cryobiopsy…
Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma
This post was originally published on this site Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and multiple myeloma. The study (NCT04136756) is recruiting up to 82 patients across multiple U.S. sites and also will…









